Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib + cetuximab versus chemotherapy in second-line KRAS G12C-mutant advanced colorectal cancer
NL-OMON54310Phase 3Recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adagrasib and cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Progression-Free Survival and Overall Survival. Started Jan 2023; status: recruiting.
02
Drugs
adagrasibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON54310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54310.